Saturday April 2021
This analysis is especially desirable for advanced cancer cases where
Known treatments proved to not be successful.
DNA sequencing is used to determine the sequence of individual genes, larger genetic regions (i.e. clusters of genes or operons), full chromosomes or entire genomes. The standard Sequencing methods today look for specific genetic mutations.
The new Deep Sequencing Molecular Characterization (DSMC) headed bythe Department of Pathology in conjunction
with the Department of Oncology at the Hadassah Medical Center are offering, a sequencing analysis of thousands of genetic changes which can have treatment implications.
Tests for the genetic analysis of the cancerous tissue using deep sequencing is the cutting edge technology in molecular pathology and is intended to search for new avenues of oncology treatment over and above the currently known and used options.
The DSMC analysis is performed on cancerous tissue using deep NGS (Next Generation Sequencing). This analysis includes providing additional treatment options based on the findings and their analysis by a team of oncologists, pathologist, biologists and geneticists. This new Deep Sequencing Analysis can identify both known and new mutations in clinical samples.
Routine use of the DSMC analysis in treating oncological patients is feasible, does not require a new biopsy and can judiciously affect treatment decisions. This analysis is especially desirable for advanced cancer cases where known treatments proved to not be successful. The enlargement and availability of the genetic alterations examined together with the availability of biological therapies may lead to further improvement in the clinical outcome of patients.
